Michael Wagner, MD

Michael J. Wagner, MD, explains how immunotherapy may be a promising treatment approach for patients with angiosarcoma.

Michael J. Wagner, MD, discusses molecular pathways that are becoming relevant in angiosarcoma.

Michael J. Wagner, MD, discusses known risk factors for developing angiosarcoma.

Michael J. Wagner, MD, discusses the standard of care for patients with angiosarcoma.

Michael J. Wagner, MD, discusses the challenge of diagnosing angiosarcoma.

Michael J. Wagner, MD, discusses the importance of cooperative research groups in angiocarcinoma.

Michael Wagner, MD, discusses the rationale for using immunotherapy in the treatment of patients with angiosarcoma.

Michael Wagner, MD, discusses the safety profile of nivolumab plus ipilimumab in patients with angiosarcoma.

Michael Wagner, MD, discusses responses achieved with nivolumab plus ipilimumab in patients with angiosarcoma.

Michael Wagner, MD, discusses future research efforts in sarcoma subtypes.

Michael Wagner, MD, discusses the potential use of immunotherapy in patients with angiosarcoma.